Pembrolizumab

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13021 publications

Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy.

Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy.

Journal: JCO oncology practice

Published: June 23, 2026

Second and subsequent lines of systemic therapy in endometrial cancer - a real-life clinical experience.

Second and subsequent lines of systemic therapy in endometrial cancer - a real-life clinical experience.

Journal: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti

Published: June 22, 2026

No RFS benefit found from adding vibostolimab to pembrolizumab in patients with high-risk melanoma: Adding the anti-TIGIT antibody vibostolimab to adjuvant pembrolizumab failed to improve recurrence-free survival and increased toxicity.

No RFS benefit found from adding vibostolimab to pembrolizumab in patients with high-risk melanoma: Adding the anti-TIGIT antibody vibostolimab to adjuvant pembrolizumab failed to improve recurrence-free survival and increased toxicity.

Journal: Cancer

Published: June 19, 2026

Pembrolizumab-associated choroidal inflammation on a background of treated choroidal melanoma.

Pembrolizumab-associated choroidal inflammation on a background of treated choroidal melanoma.

Journal: BMJ case reports

Published: June 19, 2026

Chronotherapeutic Considerations in Immunotherapy: A Case of Durable Response in Metastatic Non-small Cell Lung Cancer.

Chronotherapeutic Considerations in Immunotherapy: A Case of Durable Response in Metastatic Non-small Cell Lung Cancer.

Journal: Prague medical report

Published: June 19, 2026

Flexible Survival Extrapolation with Blended Hazards: Accounting for Treatment Effect Waning in Health Technology Assessment.

Flexible Survival Extrapolation with Blended Hazards: Accounting for Treatment Effect Waning in Health Technology Assessment.

Journal: Medical decision making : an international journal of the Society for Medical Decision Making

Published: June 19, 2026

Pembrolizumab Plus Quad-Shot Radiotherapy for Recurrent, Unresectable, or Metastatic Head and Neck Cancer: A Nonrandomized Clinical Trial.

Pembrolizumab Plus Quad-Shot Radiotherapy for Recurrent, Unresectable, or Metastatic Head and Neck Cancer: A Nonrandomized Clinical Trial.

Journal: JAMA otolaryngology-- head & neck surgery

Published: June 18, 2026

Maintenance Pemetrexed/Pembrolizumab Versus Pembrolizumab in Non-Small Cell Lung Cancer: A Propensity Score-Weighted Analysis.

Maintenance Pemetrexed/Pembrolizumab Versus Pembrolizumab in Non-Small Cell Lung Cancer: A Propensity Score-Weighted Analysis.

Journal: JCO oncology practice

Published: June 18, 2026

Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. Reply.

Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. Reply.

Journal: The New England journal of medicine

Published: June 17, 2026

Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer.

Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer.

Journal: The New England journal of medicine

Published: June 17, 2026

Effectiveness and cost-effectiveness of pembrolizumab in persistent, recurrent, or metastatic cervical cancer with PD-L1 CPS 1-10: secondary analysis of KEYNOTE-826 using innovative KMSubtraction.

Effectiveness and cost-effectiveness of pembrolizumab in persistent, recurrent, or metastatic cervical cancer with PD-L1 CPS 1-10: secondary analysis of KEYNOTE-826 using innovative KMSubtraction.

Journal: Expert review of pharmacoeconomics & outcomes research

Published: June 16, 2026

Autoantibodies Drive Fcγ Receptor-Dependent Colon Inflammation During Immune Checkpoint Blockade.

Autoantibodies Drive Fcγ Receptor-Dependent Colon Inflammation During Immune Checkpoint Blockade.

Journal: bioRxiv : the preprint server for biology

Published: June 12, 2026

Showing 1-12 of 13,021

Last Updated: 06/30/2026